Wave_Rider
reacted to
$Sensei Biotherapeutics (SNSE.US)$ And 18.13 broke and in the bag! Yes don’t applaud, Just throw money! Hehehe![]()
💸🥂
9
9
Wave_Rider
liked and commented on
$Recursion Pharmaceuticals (RXRX.US)$ Upcoming Milestones:
•REC-4881 (MEK1/2): Additional data in FAP from the Phase 2 TUPELO study expected in December 2025! BUT able to NARROW it down now! They are participating in a conference on 12/8/25 and are supposed to release the data there!
•REC-4881 (MEK1/2): Additional data in FAP from the Phase 2 TUPELO study expected in December 2025! BUT able to NARROW it down now! They are participating in a conference on 12/8/25 and are supposed to release the data there!
3
4
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Wave_Rider
reacted to
$Accuray (ARAY.US)$ So much fun when people like to “Correct” Me or give me “Solid Advice” Hehehe! Which if they were close to correct? Im all for listening and saying thank you! But when they cant even BOTHER to see if they were / are close to correct before “Helping” me understand the Market! Well thats too funny! Hehehe!
As you will see from screenshot! This person told me my Post of news Dont matter because the price dont move until they “Schedule” it to rise! Hehehe! But if you look ...
As you will see from screenshot! This person told me my Post of news Dont matter because the price dont move until they “Schedule” it to rise! Hehehe! But if you look ...
6
13
Wave_Rider
reacted to
$Intensity Therapeutics (INTS.US)$ Will be giving Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium December 9 to 12, 2026
7
3
Wave_Rider
liked
$Repare Therapeutics (RPTX.US)$ Hmm So they presented data on the LIONS RP-1664 TRIAL First-in-class, oral selective PLK4 Inhibitor at conference mid November!
But my notes say that there is still a Upcoming expected milestone in
Q4 2025 for Topline safety, tolerability and early efficacy data from the POLAR RP-3467 trial in monotherapy and in combination with olaparib. So I do believe this is a Heads-Up! He...
But my notes say that there is still a Upcoming expected milestone in
Q4 2025 for Topline safety, tolerability and early efficacy data from the POLAR RP-3467 trial in monotherapy and in combination with olaparib. So I do believe this is a Heads-Up! He...
3
Wave_Rider
reacted to
$Milestone Pharmaceuticals (MIST.US)$ But im very confident that it will be approved! As you will see in the companys own words in parentheses last sentence below! They are so confident that they are already prepared for whats next after / IF approved! ANYWAYS heres the heads-up. PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT)! And below if the quote from the company that i add...
4
11
Wave_Rider
reacted to
$Taoping (TAOP.US)$ And that would be 4.19 Broke💸🥂
4
4
Wave_Rider
reacted to
⚠️ READ THIS BEFORE YOU TRADE ⚠️
1. NFA — Nothing here is financial advice. I am not your financial advisor, and this is NOT a buy/sell alert.
2. Trade with confirmation. Always check the chart, volume, momentum, order book, and short availability before touching a position.
3. Manage risk like a pro. Scale out, take profits, use stops. If you’re guessing instead of planning, you’re gambling.
4. Your P&L is yours. Wins are yours to celebrate, lo...
1. NFA — Nothing here is financial advice. I am not your financial advisor, and this is NOT a buy/sell alert.
2. Trade with confirmation. Always check the chart, volume, momentum, order book, and short availability before touching a position.
3. Manage risk like a pro. Scale out, take profits, use stops. If you’re guessing instead of planning, you’re gambling.
4. Your P&L is yours. Wins are yours to celebrate, lo...
33
9
6
Wave_Rider
reacted to
$PharmaCyte Biotech (PMCB.US)$ Looks like their investment in $Femasys (FEMY.US)$ Is liked a fair bit by the market! Hehehe
7
2
Wave_Rider
reacted to
$Ovid Therapeutics (OVID.US)$ OV329 Phase 1 results selected for late-breaking poster presentation at the 2025 American Epilepsy Society (AES) annual meeting December 5 to 9 2025!!!! ALSO
Ovid’s first-in-class KCC2 direct activator portfolio is progressing on-track with first-in-human data for OV350 intravenous (IV) expected in Q4 2025
Ovid’s first-in-class KCC2 direct activator portfolio is progressing on-track with first-in-human data for OV350 intravenous (IV) expected in Q4 2025
8
10
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)